secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001127537-25-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q3 rev $21.5M (+5%), net loss $14.0M; guides FY rev $89-90M; adds COO role
--------------------------------------------------------------------------------

- Worldwide revenue $21.5M (+5% YoY); US $14.0M (+1%), Intl $7.5M (+15%).
- Gross margin 75% vs 74% YoY; net loss $14.0M ($0.34/share) vs $14.1M ($0.36) YoY.
- Adjusted EBITDA loss $8.2M vs $8.1M YoY; cash $76.5M.
- FY2025 revenue guidance narrowed to $89-90M; operating expenses $125-126M incl ~$21M SBC.
- Glen French reappointed CEO; Derrick Sung appointed COO & CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000058/0001127537-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000058/lung-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001127537-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer